nash tirzepatide SYNERGY-NASH: Tirzepatide, a GIP/GLP-1 RA, Resolves MASH Without Worsening Fibrosis Post-hoc analysis of SYNERGY-NASH trial

Many patients start with Semaglutide and later transition to Tirzepatide under physician guidance

Although both contain semaglutide, compounded semaglutide products are not FDA-approved and have not been tested for safety, effectiveness, or quality in the same way as an FDA-approved drug like Wegovy

We classified prescriptions of Wegovy (approved for overweight and obesity) as on-label if the patient had a history of BMI 27 or documentation of obesity, and off-label otherwise

Which is safer

While oral supplements are convenient and accessible, they often have lower absorption rates than other forms, meaning that only a fraction reaches the liver